Clinical Trial Update: A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating tildrakizumab for moderate to severe plaque psoriasis in Chinese patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Tildrakizumab (tildrakizumab)

Snippet

Sponsor: Shenzhen Kangzhe Pharmaceutical Co., Ltd. | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED